A Double-blind, randomized, placebo-controlled study to assess the safety, antiviral activity and pharmacokinetics of GSK2336805 when given as monotherapy and in combination with peginterferon alfa-2a and ribavirin in hepatitis C virus genotype 1-infected

2013 ◽  
Vol 34 (6) ◽  
pp. e89-e95 ◽  
Author(s):  
Stephen Gardner ◽  
Amy Cutrell ◽  
Cindy Elko-Simms ◽  
Kimberly Adkison ◽  
Robert Hamatake ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Antiviral Activity ◽  
Controlled Study ◽  
Genotype 1 ◽  
Virus Genotype ◽  
Double Blind ◽  
Peginterferon Alfa

Impact of Ribavirin Dose Reductions in Hepatitis C Virus Genotype 1 Patients Completing Peginterferon Alfa-2a/Ribavirin Treatment

2007 ◽  
Vol 5 (1) ◽  
pp. 124-129 ◽  
Author(s):  
K. Rajender Reddy ◽  
Mitchell L. Shiffman ◽  
Timothy R. Morgan ◽  
Stefan Zeuzem ◽  
Stephanos Hadziyannis ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Genotype 1 ◽  
Virus Genotype ◽  
Peginterferon Alfa ◽  
Dose Reductions

scholarly journals Randomized trial of peginterferon alfa-2b and ribavirin for 48 or 72 weeks in patients with hepatitis C virus genotype 1 and slow virologic response

Hepatology ◽  
2010 ◽  
Vol 52 (4) ◽  
pp. 1201-1207 ◽  
Author(s):  
Maria Buti ◽  
Yoav Lurie ◽  
Natalia G. Zakharova ◽  
Natalia P. Blokhina ◽  
Andrzej Horban ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Randomized Trial ◽  
Virologic Response ◽  
Genotype 1 ◽  
Virus Genotype ◽  
Peginterferon Alfa
Sign in / Sign up

Export Citation Format

Share Document